Paskaitos medžiaga (video)


Literatūros sąrašas:

1.Valadkevičienė D, Kavaliunas A, Kizlaitiene R et el. Incidence rate and sex ratio in multiple sclerosis in Lithuania. Brain Behav. 2018 Nov.

2.Kizlaitiene R, Budrys V. Prevalence of multiple sclerosis in Lithuania and the influence of immunomodulating treatment on annual hospitalization. Multiple sclerosis  

4.Milo ompston A, Canfavreux C, McDonald I, et al. (Eds). McAlpine`s Multiple Sclerosis. 4th edition. Philadelphia: Churchill R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun. Rev. 2010;9:A387–A394.

5.O׳Conor PW, Marriott JJ. Differential diagnosis and diagnostic criteria for multiple sclerosis: application and pitfalls. In: Lucchinetti C,Hohlfeld R. (Eds). Multiple sclerosis 3. 1st edition. Philadelphia: Saunders Elsevier, 2010;19-42.

6.Gregory SG, et al. Nat Genet 2007: published online: 29 July 2007. doi:10.1038/ng2103;

7.Dyment DA et al. Genetics of multiple sclerosis. Lancet Neurol 2004;3:104–110.

8.Barcellos LF et al HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 2003;72:710–716.

9.Balnyte R et al . Frequency of HLA-DRB1 Gene Alleles in Patients With Multiple Sclerosis in a Lithuanian Population. Medicina. 2012 Feb 22;48(1).

Schwarz T.  Mechanisms of UV-induced immunosuppression. Keio J Med 2005;54:165–171.

11.Sobel RA, Moore GRW. 2008. Demyelinating diseases. In Greenfield`s Neuropathology, ed. S Love, DN Louis, DW Ellison, pp. 1513–608. New York: Oxford Univ. Press.

Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends in molecular medicine, 2001.

13.Dittel B. Brain Behav Immun 2008;22:421–30; McFarland HF et al. Nat Immunol 2007;8:913–19; Sospedra M et al. Annu Rev Immunol 2005;23:683–47.

14.Noseworthy JH et al. Multiple sclerosis. N Engl J Med 2000;343:938–52.

15.Compston A, Canfavreux C, McDonald I, et al. (Eds). McAlpine`s Multiple Sclerosis. 4th edition, 2006.

16.Frischer JM, et al. Clinical and pathological insights into dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710–21;

17.Feuillet L, Reuters F, Audoin B eta al. Early cognitive impairment in patients with clinically isolated sindrome suggestive of multiple sclerosis. Mult Scler2007;13:124-127.

18.Patti F. Cognitive impairment in multiple sclerosis. Mult Scler 2009;15(1):2-8.

19.Noseworthy JH, Kirkpatrick K. Natalizumab. Nat Rev Drug Discov 2005;4(2):101–2.

20. Koch M et al. The natural history of a secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81(9):1039–43.

21. Scalfari A et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability, Brain 2010;133(Pt 7):1914–29.

22.Koch M et al. Factors associated with the risk of secondary progression in multiple sclerosis. Mult Scler 2008;14(6):799–803.

23.Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 2013;19(17Comparison of two dosing freaquencies of subcutaneous interferon beta1a in patients with a first clinical demyelinating event of multiple sclerosis (REFLEX): a phase 3 randomised clinical trialal.Suppl):S321–31.

24.Comi G et al. REFLEX: a 3 phase randomised controlled trial. Lancet Neurol 2012;11(1):33-41.

25. Kotelnikova E, et al. Dynamics and heterogenicity of brain damage in multiple sclerosis. PLOS Comp Biol 2017;13:e1005757.

26.Lubin FD. New multiple sclerosis phenotypic classification. Eur Neurol 2014;72 Suppl 1:1-5. doi: 10.1159/000367614. Epub 2014 Sep 26.

27.Kantarci OH, et al. Primary Progressive Mulltiple sclerosis Evolving from Radiologically Isolated syndrome. Ann Neurol 2016;79:288–94.

28.Wolinsky JS, Patient selection for trials. Mult Scler J 2017;23(12):1636-41.

29. Zurawski J, et al. Use of Magnetic Respnance Imaging to visualize leptomeningeal Inflammation in patients with Multiple Sclerosis: a review. JAMA Neurol 2017;74:100–9;

30.Michel L et al. B Cells in Mutiple Sclerosis Central Nervous System: trafficking and contribution to CNS- compartmntalized inflammation. Front Immunol 2015;6:636;

31.Baker D et al. Memory B Cells are major targets for effective immunotherapy in relapsing Multipe sclerosis. EBioMedicine 2017;16:41–50;

32.Bittner S et al. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord 2017;10:51–66.

33.Ziemssen T, et al. Optimizing treatment success in Multiple sclerosis. Neurol 2016;263:1053–65.

34.Valadkeviciene D, Kavaliunas A, Kizlaitiene R. Incidence rate and sx ratio in multiple sclerosis in Lithuania. Brain Behav. 2019; 19(1):e01150.doi:10.1002/brb3.1150.